Overview
Evolus Q2 2025 global net revenue rises 4% to $69.4 mln
Company expects meaningful profitability in Q4 2025
Launch of Evolysse drives revenue growth amid U.S. market challenges
Outlook
Evolus expects 2025 revenue between $295 mln and $305 mln
Company anticipates Q4 2025 profitability and annual profitability in 2026
Evolus plans to launch Evolysse™ Sculpt in 2026 and Lips in 2027
Company targets $700 mln revenue and 20% margin by 2028
Result Drivers
EVOLYSSE LAUNCH - Evolysse generated $9.7 mln in Q2 2025, marking a strong debut in the filler market
INTERNATIONAL GROWTH - Strong international sales contributed significantly to revenue increase
U.S. MARKET CHALLENGES - U.S. toxin demand softened due to decreased consumer sentiment, impacting sales
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Product Revenue |
| $68.70 mln |
|
Q2 Net Income |
| -$17.14 mln |
|
Q2 Gross Margin |
| 65.3% |
|
Q2 Adjusted Gross Margin |
| 66.5% |
|
Q2 Gross Profit |
| $45.32 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Evolus Inc is $23.50, about 61.2% above its August 4 closing price of $9.11
The stock recently traded at 43 times the next 12-month earnings vs. a P/E of 56 three months ago
Press Release: ID:nBw9GDP4a